AGN - Novartis And Tropifexor In NASH And The Market Assessment
Market Assessment
Novartis AG (NVS) is a Swiss (Basel, Switzerland) multi-billion biopharmaceutical company with a market cap of $217 billion and a broad therapeutic portfolio that encompasses many facets of biomedical science, including immunology, oncology, respiratory, neuroscience, ophthalmology, cell and gene therapy.
Novartis could have been at the forefront of NASH therapeutics development given its history with blockbuster therapeutics, Lescol, for cardiovascular and metabolic disorders. Lescol was approved by the FDA in 2000 for the use as an adjunct to diet to positively regulate hypercholesterolemia and dyslipidemia by reducing elevated total cholesterol, LDL-C,